Description
ZERO OUT OMEPRAZOLE 20 MG ORDER WITH GOLDEN STATE MEDICAL SUPPLY FOR REPACKAGING PROGRAM.
Base award description: OMEPRAZOLE 20 MG ORDER WITH GOLDEN STATE MEDICAL SUPPLY FOR REPACKAGING PROGRAM.
Modification chain · 2 transactions
Each row is one published transaction. This action is the obligation recorded on that transaction — a change amount, as USAspending publishes it. Running total is computed by Glassbox VA as the cumulative sum of those amounts up to and including the row, so the last running total equals the award's net obligations shown above. The cumulative-total columns in the source files are not used: they are not frozen per modification.
- Base2023-09-06+$431,600= $431,600
- Mod P000012023-10-24-$3,192= $428,408
| Transaction | Action date | This action (delta) | Running total | Description on this transaction |
|---|---|---|---|---|
| Base | 2023-09-06 | +$431,600 | $431,600 | OMEPRAZOLE 20 MG ORDER WITH GOLDEN STATE MEDICAL SUPPLY FOR REPACKAGING PROGRAM. |
| Mod P00001· FUNDING ONLY ACTION | 2023-10-24 | −$3,192 | $428,408 | ZERO OUT OMEPRAZOLE 20 MG ORDER WITH GOLDEN STATE MEDICAL SUPPLY FOR REPACKAGING PROGRAM. |
Related awards · 11
Awards are related by an explicit link in the data, stated for each group below — never by text similarity. Values are net obligations.
Other VA awards to the same recipient (UEI GQLDJJ8AQNN5)
| Award | Office · PSC / listing | Net obligations | FY |
|---|---|---|---|
| 36E79726D0041 | NAC PHARMACEUTICALS (36E797) · 6505 · DRUGS AND BIOLOGICALS | $0 | FY2026 |
| 36E79726D0042 | NAC PHARMACEUTICALS (36E797) · 6505 · DRUGS AND BIOLOGICALS | $0 | FY2026 |
| 36E79726D0022 | NAC PHARMACEUTICALS (36E797) · 6505 · DRUGS AND BIOLOGICALS | $0 | FY2026 |
| 36E79726D0014 | NAC PHARMACEUTICALS (36E797) · 6505 · DRUGS AND BIOLOGICALS | $0 | FY2026 |
| 36E79726D0023 | NAC PHARMACEUTICALS (36E797) · 6505 · DRUGS AND BIOLOGICALS | $0 | FY2026 |
| 36E79726D0018 | NAC PHARMACEUTICALS (36E797) · 6505 · DRUGS AND BIOLOGICALS | $0 | FY2026 |
Other recipients under 6505 from NAC PHARMACEUTICALS (36E797) (most recent first)
| Award | Recipient | Office | Net obligations | FY |
|---|---|---|---|---|
| 36E79726A0025 | CHIESI USA INC | NAC PHARMACEUTICALS (36E797) | $0 | FY2026 |
| 36E79726A0024 | NEUROTECH PHARMACEUTICALS, INC | NAC PHARMACEUTICALS (36E797) | $0 | FY2026 |
| 36E79726A0023 | TAKEDA PHARMACEUTICALS AMERICA, INC. | NAC PHARMACEUTICALS (36E797) | $0 | FY2026 |
| 36E79726A0022 | AURINIA PHARMA US INC | NAC PHARMACEUTICALS (36E797) | $0 | FY2026 |
| 36E79726A0021 | ALEXION PHARMACEUTICALS INC | NAC PHARMACEUTICALS (36E797) | $0 | FY2026 |
Cite as: Glassbox VA record view · VA contract (USAspending / FPDS) · CONT_AWD_36E79723N0040_3600_36E79720D0014_3600 · retrieved 2026-09-26.